Moody's upgrades Eli Lilly

Moody's Investors Service said it upgraded the senior unsecured long-term ratings of Eli Lilly and Co. to A1 from A2 and revised the outlook to stable from positive.

“The upgrade reflects Moody's expectations for a substantial increase in Lilly's revenue, earnings and cash flow stemming from recent and upcoming product launches. These include continuation of strong growth of Mounjaro in type 2 diabetes and the anticipated approvals and launches of tirzepatide in obesity and donanemab in Alzheimer's disease,” the agency said in a press release.

The stable outlook indicates robust growth and conservative financial policies, moderated by its ongoing concentration in the diabetes/metabolic therapeutic category.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.